{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-012025-04-011111100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-012025-04-011111100
Download SVG
Download PNG
Download CSV

Raiffeisen Research Adds Vonovia to Top Picks Amid Attractive Valuation

Raiffeisen Research has added Vonovia to its Top Picks list, citing its attractive valuation with a price-to-book ratio of around 0.8 amid rising yields. The demand for rentals in Germany is expected to remain strong due to affordability issues and a shortage of new buildings, while recent interest rate cuts are lowering refinancing costs. The updated Top Picks include notable companies such as 3M, Amazon, and Microsoft, alongside Vonovia.

high potency active pharmaceutical ingredients market trends and future growth prospects

The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.

Navina secures 55 million dollars in series C funding from Goldman Sachs

Clinical AI leader Navina has successfully raised $55 million in Series C funding, with the round led by Growth Equity at Goldman Sachs Alternatives. This investment highlights the growing interest in AI technologies within the healthcare sector.

Chinese premier advocates dialogue with US amid rising trade tensions

Chinese Premier Li Qiang urged for dialogue over confrontation during a meeting with U.S. Senator Steve Daines, emphasizing the need for cooperation amid rising tensions over trade tariffs and fentanyl trafficking. Daines, a supporter of President Trump, is the first U.S. lawmaker to visit Beijing since Trump took office, and he coordinated closely with the White House on these issues. Li highlighted the importance of fair competition and the necessity for both nations to work together to ensure stable relations.

Accenture shares drop as government contract cancellations impact revenue outlook

Accenture's stock plummeted 7% following the cancellation of several multi-million dollar contracts due to cost-cutting measures by Elon Musk’s Department of Government Efficiency. CEO Julie Sweet noted a slowdown in securing new US government contracts, which account for 8% of the company's revenue, and acknowledged ongoing uncertainties as federal priorities shift. Despite the challenges, Sweet expressed optimism about future opportunities to enhance government efficiency.

Pfizer raises 2.4 billion pounds from Haleon stake sale

Pfizer has successfully sold 618 million shares of Haleon at 385 pence each, raising approximately £2.4 billion in gross proceeds. Additionally, Haleon will conduct an off-market purchase of about 44 million ordinary shares from Pfizer for around £170 million.

indonesia faces economic crisis as mass layoffs surge across sectors

Indonesia is facing a significant economic crisis, highlighted by a 20.2% increase in mass layoffs across various sectors, resulting in 78,000 job losses in 2024 alone. The manufacturing sector, once a cornerstone of the economy, has seen its contribution to GDP plummet from 32% in 2002 to just 18% in 2024, signaling a troubling trend of premature deindustrialization. Analysts urge the government to implement swift fiscal and monetary incentives to combat the economic downturn.

Pfizer reports strong fourth quarter results and maintains positive 2025 outlook

Pfizer's shares have shown mixed performance recently, with a slight decline to EUR 24.50 on February 13, 2025, following a positive trading day that saw a rise to EUR 25.22. The company reported a 7% increase in annual revenue to $63.6 billion for 2024, driven by strong sales of Covid-19 drugs and other key products, while maintaining a shareholder-friendly dividend policy. Analysts have adjusted their price targets, with ratings ranging from "Buy" to "Neutral," reflecting a cautious but optimistic outlook for 2025.

ubs assigns neutral rating to pfizer inc amid investment risks

UBS has rated PFIZER INC as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing carries risks, including the potential loss of capital, and expert investment advice is recommended.

ubs maintains neutral rating for pfizer with target price of 29 dollars

UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $29. Analyst Trung Huynh noted a solid fourth quarter and highlighted the pharmaceutical company's confirmed outlook for 2025 in a recent study published on February 4, 2025.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.